1731 Stock Overview
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$18.00|
|52 Week High||NT$24.20|
|52 Week Low||NT$16.60|
|1 Month Change||-3.74%|
|3 Month Change||7.46%|
|1 Year Change||-2.97%|
|3 Year Change||36.36%|
|5 Year Change||31.87%|
|Change since IPO||-14.95%|
Recent News & Updates
|1731||TW Personal Products||TW Market|
Return vs Industry: 1731 matched the TW Personal Products industry which returned -3.5% over the past year.
Return vs Market: 1731 exceeded the TW Market which returned -18% over the past year.
|1731 Average Weekly Movement||2.9%|
|Personal Products Industry Average Movement||5.7%|
|Market Average Movement||5.1%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.4%|
Stable Share Price: 1731 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 1731's weekly volatility (3%) has been stable over the past year.
About the Company
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. It offers hair care products; health care products and food supplements; and mother and baby skin care products under the mustela brand. The company also provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition.
Maywufa Fundamentals Summary
|1731 fundamental statistics|
Is 1731 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1731 income statement (TTM)|
|Cost of Revenue||NT$430.34m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.20|
|Net Profit Margin||12.28%|
How did 1731 perform over the long term?See historical performance and comparison
6.5%Current Dividend Yield
Is 1731 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1731?
Other financial metrics that can be useful for relative valuation.
|What is 1731's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1731's PE Ratio compare to its peers?
|1731 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
6703 Shiny Brands Group
1796 GeneFerm Biotechnology
1783 Maxigen Biotech
8480 Taisun Int'l (Holding)
Price-To-Earnings vs Peers: 1731 is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (22.7x).
Price to Earnings Ratio vs Industry
How does 1731's PE Ratio compare vs other companies in the Asian Personal Products Industry?
Price-To-Earnings vs Industry: 1731 is good value based on its Price-To-Earnings Ratio (15x) compared to the Asian Personal Products industry average (25.7x)
Price to Earnings Ratio vs Fair Ratio
What is 1731's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1731's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 1731 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1731 (NT$18) is trading above our estimate of fair value (NT$14.22)
Significantly Below Fair Value: 1731 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Maywufa forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maywufa has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Maywufa's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Maywufa performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1731 has high quality earnings.
Growing Profit Margin: 1731's current net profit margins (12.3%) are lower than last year (14.1%).
Past Earnings Growth Analysis
Earnings Trend: 1731's earnings have grown by 15.9% per year over the past 5 years.
Accelerating Growth: 1731's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1731 had negative earnings growth (-4.4%) over the past year, making it difficult to compare to the Personal Products industry average (-11.6%).
Return on Equity
High ROE: 1731's Return on Equity (8.3%) is considered low.
Discover strong past performing companies
How is Maywufa's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1731's short term assets (NT$999.0M) exceed its short term liabilities (NT$457.7M).
Long Term Liabilities: 1731's short term assets (NT$999.0M) exceed its long term liabilities (NT$6.3M).
Debt to Equity History and Analysis
Debt Level: 1731 is debt free.
Reducing Debt: 1731 has no debt compared to 5 years ago when its debt to equity ratio was 11.8%.
Debt Coverage: 1731 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1731 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Maywufa current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Maywufa Dividend Yield vs Market|
|Market Bottom 25% (TW)||2.6%|
|Market Top 25% (TW)||7.0%|
|Industry Average (Personal Products)||3.8%|
|Analyst forecast in 3 Years (Maywufa)||n/a|
Notable Dividend: 1731's dividend (6.5%) is higher than the bottom 25% of dividend payers in the TW market (2.59%).
High Dividend: 1731's dividend (6.5%) is low compared to the top 25% of dividend payers in the TW market (7%).
Stability and Growth of Payments
Stable Dividend: 1731's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1731's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (97.5%), 1731's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (256.2%), 1731's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Maywufa has no CEO, or we have no data on them.
Experienced Board: 1731's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Maywufa Company Ltd.'s employee growth, exchange listings and data sources
- Name: Maywufa Company Ltd.
- Ticker: 1731
- Exchange: TWSE
- Founded: 1976
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: NT$2.392b
- Shares outstanding: 132.92m
- Website: https://www.maywufa.com.tw
- Maywufa Company Ltd.
- No. 167, Fuxing North Road
- 5th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1731||TWSE (Taiwan Stock Exchange)||Yes||Common Stock||TW||TWD||Aug 1999|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.